Overview

Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

Single Center, open label, Phase I-II trial designed to test the safety and efficacy of the combination of Ataluren and Pembrolizumab for the treatment of metastatic mismatch repair deficient and proficient colorectal adenocarcinoma and metastatic mismatch repair deficient endometrial carcinoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators:

Merck Sharp & Dohme Corp.
PTC Therapeutics

Treatments:

Pembrolizumab